News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InNexus Inc. Enters R&D Agreement Targeting Cancer With BioInvent Of Sweden, Appoints New Chairman Of The Board Of Directors


9/27/2006 10:41:40 AM

VANCOUVER, British Columbia--(BUSINESS WIRE)--InNexus Biotechnology, Inc. (TSX VENTURE:IXS) (OTCBB:IXSBF), an innovative antibody-driven drug development company, today announced that it has entered into an R&D agreement with BioInvent International AB, a publicly-traded biotech firm, for the provision of InNexus’ SuperAntibody™ Technology with a BioInvent therapeutic antibody, targeting cancer. Under the agreement the Parties will perform collaborative R&D aimed at a single target. The agreement also contains terms for future drug development including commercialization. Financial terms of the transaction were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES